Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease;Znaczenie kliniczne interleukiny 6 (IL-6) jako czynnika rokowniczego w chorobie nowotworowej

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 5-6, 2007, Pages 247-251

  Łukaszewicz, Marta ^a   Mroczko, Barbara ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cancer; Interleukin 6

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY;

ANGIOGENESIS; APOPTOSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; COLORECTAL CANCER; CORRELATION ANALYSIS; ENDOMETRIUM CANCER; HEMATOPOIESIS; HUMAN; IMMUNOREGULATION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROTEIN FUNCTION; REVIEW; STOMACH CANCER; TUMOR GROWTH;

EID: 34948823889     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.144     Document Type: Review

References (40)

1. Gadina M, Hilton D, Johnson JA, et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol. 2001; 13: 363-373.
2. Kishimoto T. Interieukin-6: discovery of pleiotropic cytokine. Arthiritis Res Ther. 2006; 8 (Suppl 2): S2.
3. Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005; 95: 497-505.
4. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predictors survival in patients with metastatic breast cancer. Int J Cancer. 2003; 103: 642-646.
5. Golab J, Jakobisiak M, Lasek W, et al. Cytokiny. Immunologia. Warszawa, Wyd Nauk PWN, 2002; 15: 198-205.
6. Robak T. Biologia i farmakologia cytokin. Warszawa, Wyd Nauk PWN, 1995; 9: 122-133.
7. Jȩdrzejczak W. Cytokiny. Wrocław, Volumed, 1997; 4: 33-50.
8. Scheller J, Ohnesorge N, Rose-John S, et al. Interleukin-6 (IL-6) trans-signaling in chronic inflammation and cancer. Scand J Immunonol. 2006; 63: 321-329.
9. Hsu HC, Lee YM, Tsai WH, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblasts leukemia and myelodysplastic syndrome. Oncology. 2002; 63: 64-69.
10. Huang SP, Wu MS, Shun CT, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric cercinoma. J Biomed Sci. 2004; 11: 517-527.
11. Ulimann CD, Schlom J, Greiner JW. Interieukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. J Immunother. 1992; 12: 231-241.
12. Paul-Pletzer K. Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today. 2006; 42: 559-576.
13. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006; 2: S4.
14. Ueyama M, Maruyama I, Osame M. Marked increase in plasma interleukin-6 in burn patients. J Lab Clin Med. 1992; 120: 693-698.
15. Gaini S, Koldkjaer OG, Pedersen C. Procalcitonin, lipopolysaccharide- binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care. 2006; 10: R53.
16. Chen CC, Wang SS, Lee FY, et al. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol. 1999; 94: 213-218.
17. Pihusch M, Pihusch R, Fraunberger P, et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol. 2006; 76: 93-101.
18. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol. 1990; 144: 480-484.
19. Brozek W, Bises G, Girsch T, et al. Differentiation-dependent expression and myogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumor progression. Eur J Cancer. 2005; 41: 2347-2354.
20. Bellone S, Watts K, Cane S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005; 98: 92-98.
21. Songur N, Kuru B, Kalkan F, et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumor. 2004; 90: 196-200.
22. Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000; 7: 133-138.
23. Negrier S, Perol O, Menetrier-Caux C, et al. Interleukin-6, interieukin-10, and vascular ednothelial growth factor in metastatic renal cell carcinoma: prognostic value of interieukin-6. J Clin Oncol. 2005; 23: 1044-1045.
24. Zakrzewska I, Pozański J. Changes of serum IL-6 and CRP after chemiotherapy in patients with ovarian carcinoma. Pol Merk Lek. 2001; 11: 210-213.
25. Garcia-Tunon I, Ricote M, Ruiz A, et al. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology. 2005; 47: 82-89.
26. Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumor Biol. 2005; 26: 186-194.
27. Nikiteas NI, Tzanakis N, Gazouli M. Serum IL-6, TNFalpha and CRP levels in Geek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005; 11: 1639-1643.
28. Esfandi F, Mohammadzadeh Ghobadloo S, Basati G. Interieukin-6 level in patients with colorectal cancer. Cancer Lett. 2006; 244: 76-78.
29. Zhang G, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 19: 1427-1432.
30. Wallner G, Ciechański A, Dabrowski A, et al. Serum level of the angiogenetic factors: IL-6 and IL-8 in patients with gastric cancer. Asian J. Surg. 2002; 26: 132.
31. Ashizawa T, Okada R, Suzuki Y, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer. 2005; 8: 124-131.
32. Wu CW, Wang SR, Chao MF, et al. Serum interleukin-6 reflect disease status of gastric cancer. Am J Gastroenterol. 1996; 91: 1417-1422.
33. Bartsch R, Woehrer S, Raderer M, et al. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res. 2006; 26: 3187-3190.
34. Okada S, Okusaka T, Ishii H. Elevated serum interieukin 6 levels in patients with pancreatic cancer. Jpn J Gin Oncol. 1998; 28: 12-15.
35. Miyamoto Y, Hosotani R, Doi R, et al. Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cell. Anticancer Res. 2001; 21: 2449-2456.
36. El-Far M, Founda M, Yahya R, et al. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem. 2004; 60: 253-258.
37. Lai R, O'Brien S, Maushouri T, et al. Prognostic value of plasma interieukin-6 levels in patients with chronic lymphocytic leukemia. Cancer. 2002; 95: 1071-1075.
38. Guo YQ, Chen SL. The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression. [Abstract]. Zhonghua Xue Ye Xue Za Zhi. 2006; 27: 231-234.
39. Kovacs E. Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model. Scientific World Journal. 2006; 6: 888-898.
40. Dimitriu C, Martignoni ME, Bachmann J, et al. Clinical impact of cachexia on survival and outcome of cancer patients. Rom J Intern Med. 2005; 43: 173-185.